Introduction
Iron deficiency is commonly identified in endurance runners due to prolonged training and repeated ground impacts causing iron losses through a number of potential mechanisms (1, 37) . Iron deficiency is associated with oxidative stress (16) , impaired mitochondrial electron transport and protein synthesis (1) and can lead to compromised erythropoiesis (iron deficient anaemia, IDA; 35). It is well established that when iron deficiency causes IDA it leads to impaired oxygen carrying capacity and endurance performance (8) . Although, the effect of iron deficiency non-anaemia (IDNA) is less clear, iron treatment in the form of either oral iron supplementation or parenteral iron are appealing interventions for endurance athletes with IDNA.
Iron therapy is widely reported to be effective at replenishing body iron stores (3, 8, 9, 11, 24, 40) , and in some reports has led to improvements in V ሶ O 2max (9), sub-maximal cycling efficiency and time trial performance (11), fractional utilisation of peak V ሶ O 2 (40) and total haemoglobin mass (tHb-mass; 9) in IDNA endurance athletes. However, the restoration of iron stores does not guarantee an improvement in aerobic capacity or indices of endurance performance (3, 11, 24) . Moreover, improvements in iron status following treatment are often transient, with observations of serum ferritin (sFer) returning to pre-treatment levels within weeks (23), the cause of which is currently unknown. Previous investigations into iron supplementation have largely described the outcome of the intervention but have not addressed the regulation of iron metabolism or the impact that the iron treatment may have upon it.
The peptide hormone hepcidin is the master regulator of iron metabolism. Hepcidin controls iron absorption from the diet and the export of iron from hepatocytes and macrophages (18) . Regulation of hepcidin is strongly mediated by iron availability, inflammation and hypoxia (20) , stimuli that endurance athletes may be regularly exposed to. The link between hepcidin and inflammation (7) has been established in both mice (20) and human models (17, 18) . Indeed, exercise induced increases in the inflammatory marker interleukin-6 (IL-6) have preceded increases in hepcidin in active (19) , trained (25) and well trained runners (26, 33) . However, elite athletes may experience less of an inflammatory response following exercise than those who are less well trained due to adaptation (12) , which may hypothetically alter the hepcidin response in this population. In addition, post-exercise hepcidin is correlated with baseline sFer but not IL-6, suggesting that iron availability supersedes inflammation in the regulation of hepcidin in individuals who are iron deficient (26). Therefore, the influence of iron availability on hepcidin is a key factor in the regulation of iron metabolism in iron deficient endurance athletes, yet it is currently not known how treating iron deficiency with intravenous iron will influence hepcidin and iron metabolism in elite endurance athletes.
The aim of this study was firstly to characterise the response of hepcidin and iron metabolism to iron treatment in the form of a single, high dose intravascular injection.
Furthermore, given the lack of consensus on the value of iron repletion at improving endurance performance in previous studies, a second aim was to test the hypothesis that the iron injection would enhance aerobic capacity in IDNA elite distance runners. Participants were instructed not to deviate from their normal dietary practices, to refrain from iron supplementation throughout the study and to attend all laboratory trials in a well-hydrated state, at the same time of day, and to refrain from strenuous exercise during the preceding 24 hours (h).
Materials and methods

Participants
Experimental Overview
The study used a double-blind, randomised controlled design. Participants were assigned to either an iron treatment group (n = 7) or placebo group (n = 8), ensuring males and females were split evenly between groups and completed three discontinuous incremental treadmill tests to volitional exhaustion. number on a scale from 6 (no exertion) to 20 (maximal exertion) in order to rate their overall effort over the previous 3 minute running bout.
Iron Treatment
Athletes were randomised to iron treatment or placebo injection by a researcher blinded to the treadmill test data. Athletes were blinded to the intervention received. The iron or placebo injection was given by slow intravenous injection over 10 minutes through covered syringe and tubing and the athlete's arm was shielded from vision, perfomed at a hospital location (Hospital of St John and St Elizabeth, London). The researcher (NP) who performed the iron injection did not disclose which intervention the athlete had received to the physiology testers (RB and CP) until the end of the trial period.
Haematology and Biochemistry
Venous blood was collected via venepuncture of an anticubital vein in the forearm. A 10 ml SST gel Vacutainer (BD, Oxford, England) was filled and allowed to clot for 30 min at room temperature. The sample was then centrifuged at 4 °C and 3000 rpm for 10 min. Serum was then
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drawn off by syringe and divided into 1 ml aliquots and immediately frozen at -80 °C until analysis. Serum iron (sFe), sFer and transferrin (sTf) were assayed on the Architect ci6200 platform (Abbott Diagnostics Ltd, Maidenhead, UK), with inter and intra-assay coefficients of variation (CV) of 5% and 6% respectively. Serum iron was measured using a colourmetric method, sFer was measured using a solid-phase; two-site chemiluminescent immunometric assay (ICMA), and sTf was measured using a turbidimetric method. Transferrin saturation (Tsat) was calculated using the following formula Iron x 100/transferrin x 12.57 x 2
Hepcidin was measured using an in-house immunoassay with antibodies specific for human hepcidin-25 (5). Soluble transferrin receptor (sTfR) and IL-6 were measured using commercial enzyme immunosorbent immunoassays (ELISA) using two specific monoclonal antibodies (R&D Systems, Abingdon, UK).
Blood Volume and Total Haemoglobin Mass
Blood volume and tHb-mass were assessed and calculated using the optimised carbon monoxide (CO) rebreathing method described by Schmidt and Prommer (31) . Briefly, a bolus of a known dose of CO (0.8-1.0 ml·kg -1 ) was rebreathed for 2 min using a specifically designed spirometer (Bloodtec, Bayreuth, Germany). Capillary blood samples were taken from an earlobe prior to and at 6 and 8 min after rebreathing began, and analysed for carboxyhaemoglobin (%HbCO) using spectrophotometry (OSM-80, Radiometer, Copenhagen, Denmark). CO not taken up by the subject was calculated using the volume of the rebreathing bag and the CO concentration left in it using a hand held CO gas analyser (Pac700, Drager, Lubeck, Germany).
Seven minutes after commencing rebreathing end tidal CO concentration was measured using the A C C E P T E D same CO gas analyser. tHb-mass and blood volume were then calculated using SpiCO measurement software (Bloodtec, Bayreuth, Germany). All measurements were taken 1 h following completion of the treadmill tests, with participants in a seated position 15 min prior to and throughout the procedure.
Statistical Analysis
Data were analysed using the Statistical Package for the Social Sciences (SPSS, Inc., Chicago, IL, USA). Measures of central tendency and spread are presented as mean ± SD. Sub-maximal V ሶ O 2, and blood lactate ([La]) during the three treadmill tests and changes in sFer, sFe, sTf, Tsat, sTfR and hepcidin were analysed using a mixed analysis of variance (MANOVA) with repeated measures (Treatment condition x measurement time point). A one-way analysis of variance (ANOVA) was used to analyse the effect of the iron treatment on tHb-mass, blood volume and
. When the assumption of sphericity was violated, the Greenhouse-Geisser correction was used. In the event of a significant outcome a post-hoc test with Bonferroni adjustments was applied to identify where differences lay. The level of significance was set at p < 0.05 for all analyses. In order to provide a more insightful interpretation of the data, the actual p value is given for significant outcomes.
Results
Iron Indices
There were no significant between-group differences prior to treatment (baseline) in sFer, sFe, sTf, Tsat, sTfR, Il-6 or hepcidin (figures 1, 2, 3 and table 1). After treatment a significant main effect of iron treatment group was revealed for sFer (p=0.001). Significant effects of time A C C E P T E D point (p=0.001) and time point x treatment group interaction (p=0.001) revealed that sFer increased within 24 h of the iron injection in the iron group and this was maintained during all remaining time points up to 4 weeks after treatment (figure 1). Serum ferritin did not change in the placebo group.
Prior to treatment no significant main effect of treatment group (p=0.995) or treatment group x time point interaction (p=0.943) was observed for hepcidin. However, there was a significant main effect of time point (p=0.009) but Post hoc tests were unable to identify where the effects of time point were. Twenty-four hours after the iron injection a significant main effect of treatment group was observed for hepcidin (p=0.004), with the iron group having significantly
higher hepcidin values at all time points compared to the placebo group (figure 2). There was also a significant effect of time point (p=0.016) but no significant time point x treatment group interaction (p=0.398). The Bonferroni adjustments were unable to identify where the significant time point effects lay. Four weeks after the treatment there were significant main effects of treatment group (p=0.009), time point (p=0.004) and time point x treatment group interaction (p=0.033), with the iron group having a significantly higher hepcidin response 3 h post-exercise.
Interleukin-6 increased immediately after each exercise test in both the iron and placebo groups (p=0.001; figure 3) but there were no treatment effects (p=0.659) or significant time point
x treatment group interactions (p=0.569). Serum iron (p=0.001) and Tsat (p=0.001) were significantly affected by treatment and both measures observed significant time point (p=0.001) effects and treatment group x time point interactions (p=0.001). Following the iron injection both sFe and Tsat (table 1) increased significantly within 24 h compared to the placebo group but by 4 weeks after both had returned to pre-treatment levels.
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Serum transferrin was not affected by treatment (p=0.150) and there was no treatment group x time point interaction (p=0.174). A significant effect of time point (p=0.001) was observed revealing an increase in sTf in both groups immediately after the pre-treatment treadmill test when compared to pre-test levels (table 1) . There was a significant effect of treatment group on sTfR (p=0.014) but no significant effect of time point (p=0.121) or a significant treatment group x time point interaction (p=0.163; table 1).
Red Cell Indices & Treadmill Data
Red cell indices and treadmill data are presented in tables 2 and 3 respectively. There were no significant differences between groups in red cell indices, independent increases in hepcidin following exercise observed in the present study are also in response to oxidative stress, although we do not have any data to support this contention.
Soluble transferrin receptor is considered to be an accurate marker of iron deficiency (2) and benefits from being unaffected by exercise-induced inflammation (35) . Previously, oral iron supplementation in IDNA subjects has resulted in a significant decrease in sTfR accompanied by increases in sFer (40). Conversely, sTfR was reportedly unchanged in female IDNA endurance athletes following an iron injection (24). The present investigation also found no significant changes in sTfR in either the iron or placebo group following treatment, despite increases in sFer in the iron group. The lack of change in sTfR in response to the iron injection might suggest that sTfR levels in IDNA individuals are within the normal range and despite low sFer, iron requirements and availability are not yet compromised. Furthermore, the lack of an impact upon (table 2) following the iron injection provides additional evidence that low sFer levels prior to iron treatment do not lead to any negative outcomes, notwithstanding the limitations of the present study. Moreover, the current evidence raises the possibility that clinical ranges for sFer are redundant in endurance athletes, particularly when used as a single marker of iron storage. The lack of any improvement in aerobic capacity and surrogate measures of endurance performance in the present study is in contrast to a recent investigation which reported likely improvements in tHb-mass and V ሶ O 2max following iron injection but not oral supplementation (9). However, the increases in tHb-mass observed by Garvican et al. (9) following iron injection (2.7% after 6 weeks & 1.9% after 8 weeks) fall close to and within the typical measurement error associated with CO rebreathing (2.2%; 10). Additionally, the average
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oscillation for tHb-mass in athletes over a year is 4.6% (28), which suggests it may be difficult to associate very small changes in tHb-mass to intravenous iron treatment.
The present study provides further evidence that the up-regulation of the post-exercise hepcidin response following iron treatment represents a major consideration when prescribing iron treatments for IDNA athletes. It is accepted that the up-regulation of hepcidin inhibits iron absorption from the diet and iron release to the circulation (14, 18) The present investigation is limited by a lack of dietary control. The athletes were instructed to continue with their regular dietary practice and therefore there was no control of iron intake from food sources. However, in practice it is unlikely that athletes at this level of performance would deviate dramatically from their normal diet at any one time and vast changes would be required to significantly alter total iron intake during the time course of this study.
Another limitation is the potential impact that menstrual cycle phase can have on indices of iron metabolism (34) and again, this was not controlled. However, although iron indices may be lower during menses, V ሶ O 2max , tHb-mass and the other measures of endurance capacity are unlikely to be affected by menstrual cycle phase (39). The training that the athletes undertook on a daily basis was also not under the control of this investigation, other than the standard pre-test requirement to reduce training intensity in the 24 hours prior to treadmill testing, which could have potentially influenced aerobic capacity. However, tHb-mass remains relatively stable in athletes of a highly trained status (32) and the measures of iron metabolism are also unlikely to be affected.
Conclusion
Iron treatment in the form of a single 500 mg dose of parenteral ferric carboxymaltose significantly raised sFer within 24 h and this was maintained for 4 weeks after treatment.
However, the hypothesis that improved iron status would result in the enhancement of aerobic capacity and indices of endurance capacity is rejected, as there were no significant effects on A C C E P T E D Table Legends   Table 1 . Iron metabolism data measured pre-exercise, immediately after exercise and 3 hours after exercise pre-treatment, 24 hours post-treatment and 4 weeks post-treatment. Table 2 . Red cell indices measured pre-treatment and 4 weeks post-treatment. 
